Quốc gia: Úc
Ngôn ngữ: Tiếng Anh
Nguồn: Department of Health (Therapeutic Goods Administration)
cinacalcet hydrochloride, Quantity: 66.128 mg (Equivalent: cinacalcet, Qty 60 mg)
Cipla Australia Pty Ltd
Tablet, film coated
Excipient Ingredients: microcrystalline cellulose; pregelatinised starch; crospovidone; povidone; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake
Oral
28's
(S4) Prescription Only Medicine
Cipla Cinacalcet may be used to treat the biochemical manifestations of secondary hyperparathyroidism (HPT) in patients with end stage renal disease, receiving dialysis (see section 5.1 Pharmacodynamic properties, Clinical trials). Cipla Cinacalcet should be used as adjunctive therapy.,Cipla Cinacalcet is indicated for the treatment of hypercalcaemia in patients with parathyroid carcinoma.,Cipla Cinacalcet may be used to treat the biochemical manifestations of primary HPT in patients for whom parathyroidectomy is not a treatment option.
Visual Identification: Light green coloured, oval shaped, biconvex film-coated tablets, debossed with "CL" on one side and "411" on other side; Container Type: Bottle; Container Material: HDPE; Container Life Time: 24 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure
Registered
2023-02-07